News Roundup this Week

Eli Lilly Sues Compounding Pharmacies Over Tirzepatide Products: Eli Lilly has filed lawsuits against Strive Pharmacy LLC and Empower Clinic Services LLC for selling unapproved products containing tirzepatide, the active ingredient in Lilly's weight-loss and diabetes medications. The legal actions allege that these companies falsely advertise their products as safer and more effective than FDA-approved medications by adding compounds like vitamin B12. https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-sues-two-compounders-over-copies-weight-loss-drugs-2025-04-01/

Hims & Hers Health Adds Eli Lilly's Zepbound to Telehealth Platform: Hims & Hers Health announced plans to sell Eli Lilly's weight-loss drug, Zepbound, on its telehealth platform. This move follows the FDA's ban on compounded versions of tirzepatide due to the resolution of its shortage status. The addition aims to expand Hims & Hers' weight-loss product offerings, despite the high cost of Zepbound at $1,899 per month. https://www.reuters.com/business/healthcare-pharmaceuticals/hims-hers-sell-lillys-zepbound-its-telehealth-platform-2025-04-01/

Regulatory Status of Peptide Compounding in 2025: Few peptides can be legally compounded. Must be FDA-approved, have GRAS status, USP monograph, or appear on 503A Bulks List. Suppliers must be FDA-listed with Certificate of Analysis. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/ 

Featured Compounding Formula

Need a formula? Request one here for free! https://503pharma.com/formulas

Featured Blog Article

 Thank you